Which statement is true for patients prescribed buprenorphine for opioid use disorder who experience acute pain?

Patients prescribed buprenorphine for opioid use disorder who experience acute pain can indeed be treated with opioids without significantly increasing the risk of relapse. This is important as acute pain can occur for various reasons, including surgery or injury, and managing that pain effectively is crucial for the patient's overall well-being and recovery process.

Buprenorphine is a partial agonist at the mu-opioid receptor, which means it can provide some pain relief while also offering a ceiling effect that helps reduce the potential for misuse associated with full agonist opioids. When managing acute pain in these patients, clinicians can administer opioids if needed, while taking care to monitor the patient closely and manage the treatment responsibly to minimize any potential risks.

The other options do not reflect best practices for treating acute pain in patients with opioid use disorder. For instance, suggesting that acute pain is psychomatic undermines the importance of proper pain management, and the claim that multimodal approaches are ineffective is incorrect; in fact, research supports the use of various methods (including non-opioid analgesics and non-pharmacological interventions) for effective pain management in this population.